Biogen (NASDAQ:BIIB) Price Target Raised to $233.00

Biogen (NASDAQ:BIIB) had its price target lifted by Royal Bank Of Canada from $217.00 to $233.00 in a report published on Monday, Marketbeat.com reports. Royal Bank Of Canada currently has an outperform rating on the biotechnology company’s stock.

Several other analysts have also commented on BIIB. TD Cowen raised their price target on shares of Biogen from $175.00 to $215.00 and gave the company a “buy” rating in a research report on Monday. Guggenheim increased their target price on shares of Biogen from $185.00 to $246.00 and gave the stock a “buy” rating in a research note on Monday. Wells Fargo & Company lifted their price target on Biogen from $190.00 to $200.00 and gave the company an “equal weight” rating in a research note on Sunday. Truist Financial upped their price target on Biogen from $190.00 to $193.00 and gave the stock a “hold” rating in a report on Monday. Finally, Morgan Stanley set a $190.00 price objective on Biogen in a report on Sunday. Thirteen analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $206.54.

Biogen Stock Up 1.2%

Shares of BIIB opened at $191.20 on Monday. The company has a market capitalization of $28.06 billion, a price-to-earnings ratio of 21.70, a PEG ratio of 1.50 and a beta of 0.16. Biogen has a 52 week low of $110.04 and a 52 week high of $202.41. The stock’s 50-day moving average price is $177.65 and its 200-day moving average price is $158.12. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, beating the consensus estimate of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The company had revenue of $2.28 billion during the quarter, compared to analysts’ expectations of $2.21 billion. During the same period last year, the business earned $3.44 earnings per share. Biogen’s quarterly revenue was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, sell-side analysts predict that Biogen will post 15.83 EPS for the current year.

Insiders Place Their Bets

In other Biogen news, insider Priya Singhal sold 2,660 shares of Biogen stock in a transaction on Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the sale, the insider owned 8,043 shares of the company’s stock, valued at $1,607,232.69. The trade was a 24.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.18% of the company’s stock.

Hedge Funds Weigh In On Biogen

A number of institutional investors and hedge funds have recently bought and sold shares of BIIB. Rothschild Investment LLC raised its holdings in Biogen by 12.3% in the 4th quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock valued at $90,000 after acquiring an additional 56 shares during the last quarter. Advisory Services Network LLC increased its holdings in shares of Biogen by 3.9% in the third quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock valued at $251,000 after purchasing an additional 68 shares during the last quarter. CVA Family Office LLC lifted its position in Biogen by 18.1% during the third quarter. CVA Family Office LLC now owns 464 shares of the biotechnology company’s stock worth $65,000 after buying an additional 71 shares in the last quarter. Davis Investment Partners LLC boosted its stake in Biogen by 1.7% during the fourth quarter. Davis Investment Partners LLC now owns 4,374 shares of the biotechnology company’s stock worth $778,000 after buying an additional 71 shares during the last quarter. Finally, Optas LLC grew its holdings in Biogen by 4.5% in the 4th quarter. Optas LLC now owns 1,706 shares of the biotechnology company’s stock valued at $300,000 after buying an additional 73 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 beat and upbeat FY‑2026 guidance — Biogen reported Q4 results that topped EPS and revenue expectations and provided FY‑2026 EPS guidance (15.25–16.25) that reassured investors about earnings power. This is a primary driver of recent price strength. Why Biogen Is Up After Earnings
• Positive Sentiment: Analyst upgrades and higher price targets — Several firms raised targets and reiterated buys after the results (examples: Mizuho, Goldman Sachs, Canaccord, Citigroup and others), supporting further upside sentiment. Mizuho Raises Price Target
• Positive Sentiment: Regulatory progress for Leqembi (lecanemab) — The BLA for a subcutaneous formulation of Leqembi received priority review, which could expand commercial reach and margins if approved. That helped sentiment around Biogen’s Alzheimer’s growth runway. Leqembi Subcutaneous Priority Review
• Neutral Sentiment: Board leadership change — Caroline Dorsa is retiring as Board Chair; Dr. Maria C. Freire was elected Chair effective immediately. Governance continuity reduces uncertainty but is unlikely to be a major near‑term price mover. Board Chair Transition
• Neutral Sentiment: Pipeline diversification updates — Advances in lupus and SMA programs improve long‑term optionality but will take time to drive revenue; these were noted by coverage but are not immediate catalysts. Pipeline Advances
• Neutral Sentiment: Short‑interest data appears inconsistent — Recent feeds reporting a “significant increase” actually show zero shares, so no clear short‑squeeze dynamics are evident from the available data. (internal short‑interest entries)
• Negative Sentiment: Insider selling — Senior insider Priya Singhal sold 2,660 shares (~$531k), which some investors interpret as a modest negative signal about near‑term insider conviction. Insider Form 4
• Negative Sentiment: Legacy franchise pressure and execution risks — Analysts caution that MS franchise erosion and the challenges of scaling Leqembi access/commercialization could limit upside and add execution risk. Franchise Pressure Analysis

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.